STAT Plus: Merck to acquire Boston-area immunotherapy startup for up to $770 million
DR. MICHAEL SPORN VIA NIH
Merck said it would acquire Tilos Therapeutics for up to $770 million, a potentially massive windfall for a three-year-old company.
Clinical and Molecular Allergy
Hace 9 horas
No hay comentarios:
Publicar un comentario